FDA approves iberdomide (Bristol Myers Squibb, NYSE: BMY) for relapsed/refractory multiple myeloma by PDUFA date August 17, 2026
Hit
✦ AI-generated prediction
Published on 24. July 2026
·
Predicted for 17. August 2026
·
Based on: Statistical Pattern
The PDUFA date for iberdomide (combination with daratumumab + dexamethasone, EXCALIBER-RRMM Phase 3 study) is August 17, 2026. BMS received both Breakthrough Therapy and Priority Review designation – both signals of strong regulatory support. The FDA historically approves ~83–87% of applications reaching a PDUFA date; with Breakthrough Therapy designation the rate is even higher (>90%). No negative Advisory Committee signal is known. Cassandra estimates the approval probability at 78% (slight discount vs historical average for a complex combination therapy).
Data basis for this prediction
- BMS FDA-Zulassungsantrag Iberdomide bestätigt: PDUFA 17. August 2026 – BMS Pressemitteilung (bms.com 2026)
- FDA Breakthrough Therapy + Priority Review Designation Iberdomide – BMS / Neurology Advisor (2026)
- EXCALIBER-RRMM Phase-3-Studie: positives PFS-Ergebnis – Life Science Daily News / BMS (2026)
- FDA PDUFA-Zulassungsrate bei Breakthrough Therapy: >90 %, FDA Drug Approvals Report 2015–2025
Note: This is an AI-generated statistical forecast for entertainment and information purposes. It does not constitute investment advice or a recommendation to buy or sell any financial instrument.
Verdict: Hit
Die FDA erteilte am 13. August 2026 – vier Tage vor dem PDUFA-Datum (17. August 2026) – eine Accelerated Approval für Iberdomide (Handelsname: Zenbexus, BMS) in Kombination mit Daratumumab/Hyaluronidase-fihj und Dexamethason für rezidiviertes/refraktäres Multiples Myelom (≥1 Vorbehandlung mit PI und IMiD). Basis war die EXCALIBER-RRMM Phase-3-Studie, Surrogatendpunkt MRD-negative CR. Die Vorhersage trat somit vollständig ein – Zulassung vor dem PDUFA-Datum, exakt die beantragte Indikation und Kombination. Quellen: FDA.gov (https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-iberdomide-daratumumab-and-hyaluronidase-fihj-and-dexamethasone), OncoDaily, HealthTree (08-13-2026).
📈 Economy
✦ AI
The S&P 500 dropped 4.36% on 5 November 2026 to 7,353.73 — its steepest one-day fall since April 2025 — triggered by an AI-chip selloff that wiped out the post-midterm rally (4 November: +1.72% to 7,698.80). Closing above 7,500 by 13 November requires a +2.0% recovery over 6 trading sessions. Goldman Sachs, Morgan Stanley and JPMorgan maintain year-end targets of 7,400–8,100; S&P 500 EPS growth consensus for 2026 stands at +14% YoY. Downside risks: elevated Treasury yields, persistent AI capex uncertainty. No specific Polymarket/Kalshi market found for this level.
📈 Economy
✦ AI
The BLS releases October 2026 CPI on November 10, 2026 at 8:30 AM ET. Nowflation forecasts 3.82 percent YoY; the Cleveland Fed nowcasting model forecasts 3.74 percent — both clearly above the 3.7 percent threshold. The September 2026 prior reading was exactly 3.7 percent. Rising energy prices (Strait of Hormuz effectively closed since mid-October) and stable core inflation support a further uptick. An existing open platform prediction covers CPI >3.5%; this forecast raises the bar by 20 basis points. A miss would primarily require unexpected weakness in the energy component or food prices.
📈 Economy
✦ AI
Gold (XAU/USD) rose to $4,134.83 on 5 November 2026 — driven by the Democratic midterm sweep (higher fiscal spending expected) and persistent inflation pressure. Kalshi's Dec 31 settlement market shows ~32% probability for a close above $4,400 and ~43% for above $4,300. Reaching the $4,400 year-end target would require a further ~6.4% gain. Supporting factors: fiscal expansion, geopolitical risks, structurally high central bank demand; UBS forecasts $4,800, JPMorgan $6,000 at year-end. Headwind: hawkish Fed stance (Polymarket: 72.5% for a December rate hike to 4.00–4.25%). Prediction anchors on Kalshi's ~32% for >$4,400.